Omega-3 Fatty Acid Supplementation In The Management Of Chronic Lower Airway Inflammatory Conditions In Horses by Nogradi, Nora
Purdue University
Purdue e-Pubs
Open Access Theses Theses and Dissertations
2013
Omega-3 Fatty Acid Supplementation In The
Management Of Chronic Lower Airway
Inflammatory Conditions In Horses
Nora Nogradi
Purdue University, nora.nogradi@gmail.com
Follow this and additional works at: https://docs.lib.purdue.edu/open_access_theses
Part of the Veterinary Medicine Commons
This document has been made available through Purdue e-Pubs, a service of the Purdue University Libraries. Please contact epubs@purdue.edu for
additional information.
Recommended Citation
Nogradi, Nora, "Omega-3 Fatty Acid Supplementation In The Management Of Chronic Lower Airway Inflammatory Conditions In
Horses" (2013). Open Access Theses. 140.
https://docs.lib.purdue.edu/open_access_theses/140
Graduate School ETD Form 9 






This is to certify that the thesis/dissertation prepared 
 






For the degree of    
 
 
Is approved by the final examining committee: 
 
          
                                              Chair 
 
          
 
 
          
 
 
          
 
 
To the best of my knowledge and as understood by the student in the Research Integrity and 
Copyright Disclaimer (Graduate School Form 20), this thesis/dissertation adheres to the provisions of 
Purdue University’s “Policy on Integrity in Research” and the use of copyrighted material.  
 
      
Approved by Major Professor(s): ____________________________________ 
                                                      ____________________________________ 
 
Approved by:    




              
OMEGA-3 FATTY ACID SUPPLEMENTATION IN THE MANAGEMENT OF CHRONIC LOWER 
AIRWAY INFLAMMATORY DISEASES IN HORSES
Master of Science
Dr. Laurent L. Couetil
Dr. Joanne Messick
Dr. John Burgess
Dr. Laurent L. Couetil
Dr. Peter Constable 07/05/2013
	   	   	   	   iv	   	   iii	  
 
 
OMEGA-3 FATTY ACID SUPPLEMENTATION IN THE MANAGEMENT 








A Thesis  
 














In Partial Fulfillment of the 
 











West Lafayette, Indiana 





I would like to express my special thanks to Novus Nutrition Brands, LLC and Purina 
Mills, LLC for providing funding for this graduate research project. Without their support 
neither my graduate program, nor the experiments could have been carried out. 
I am very thankful to my Mentor and Major Professor Dr. Laurent L. Couëtil for 
accepting me as a graduate student, guiding me through the program, helping me setting 
up the research plan, chairing my thesis committee and participating in the experiments. 
This work could have not been carried out without his help. 
I acknowledge Dr. John Burgess and Dr. Joanne Messick, as members of my Thesis 
Committee, who provided specialized support to carry out the experiments.  
I would like to express special thanks to Donna Griffey, who actively participated in the 
experiments on a daily basis, provided invaluable technical help and support.  I would 
like to thank Dr. Kathleen Ivester and Dr. Munsiff Kamarudin; fellow graduate students 
who were a great help carrying out the experiments, as well as all the senior veterinary 
students at the Large Animal Clinic who helped with taking care of the horses during 
their clinical rotations. 
Last but not least I would like to thank all the referring veterinarians, horses and their 
owners who participated in the project.  
	      	  
	   	   	  
	  
iii	  
TABLE OF CONTENTS     
 
 
    Page 
ABSTRACT…………………………………………………………………………...…..v 
CHAPTER 1 - INTRODUCTION…...…….…...…………………………..……………..1 
CHAPTER 2 - LITERATURE REVIEW…….……………………….…..…….……...…3 
• Chronic lower airway inflammatory disease in horses……..…..…...…...........3 
• The role of oxidative stress in airway obstruction………………………….....5 
• Omega-3 polyunsaturated fatty acids in the management of respiratory 
inflammatory conditions in human medicine …………...…..…………..........6 
• Omega-3 polyunsaturated fatty acids in the management of inflammatory 
conditions in veterinary medicine………………………………………….…7 
CHAPTER 3 - MANUSCRIPT DRAFT FOR FUTURE SUBMISSION TO THE 
JOURNAL OF VETERINARY INTERNAL MEDICINE………………….……….…11 
• Introduction……….…………………………....…………….…...................11 
• Materials and methods…………..…….....…………………..……...............14 
• Results………………………….....…………………….…………...............21 
• Discussion………….……..…………………………………........................25
	      	  




   Page 
• Figures and Tables…………………………………………………………...32 
CHAPTER 4 - CONCLUSIONS…………………………..……………………….........42 
BIBLIOGRAPHY………………….…………..…..………….…………………............44 
APPENDICES 
• Appendix A: Page 1 of the VAS scoring sheet………………………………51 
• Appendix B: Page 2 of the VAS scoring sheet………………………………52 
• Appendix C: Form for the clinician assigned clinical score…………………53 
 
	      	  







Nora Nogradi. M.S., Purdue University August, 2013. Omega-3 fatty acid 
supplementation in the management of chronic lower airway inflammatory conditions in 




Chronic lower airway inflammatory diseases, such as recurrent airway obstruction (RAO) 
and inflammatory airway disease (IAD) are common in horses. RAO and IAD present 
many similarities with asthma in people. Based on studies in human asthma, omega – 3 
polyunsaturated fatty acid (PUFA) supplementation has been proposed to improve 
clinical signs in horses with chronic lower airway inflammatory disease. The purpose of 
this study was to evaluate the clinical efficacy of an omega-3 PUFA containing equine 
feed supplement (Aleira™) in horses with RAO and IAD. The study consisted of two 
separate experiments. First, a pilot study was performed in 8 research horses owned by 
Purdue University, to find the minimal effective dose that is able to alter the composition 
of phospholipid classes in plasma. Once the minimal effective dose was identified, a 
randomized, double blind, placebo controlled clinical trial was performed on client-
owned horses with a history of chronic respiratory disease (>1 month). Eligible horses 
were randomly assigned into one of 3 treatment groups fed daily for 2 months with: 30 g 
of the supplement, 60 g of the supplement or 30 g of placebo. Additionally, all horses in 
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the study were maintained on a complete pelleted diet for the duration of the study with 
no exposure to hay. Multiple clinical and clinicopathologic parameters were measured, 
and lung function testing was performed before and after the 8-week supplementation 
period. Data was analyzed using Wilcoxon matched pairs test. Data were expressed as 
median [25th-75th percentiles] and P<0.05 was considered significant. Clinical 
improvement was noted in all horses, however the group receiving the supplement had a 
greater improvement in the veterinarian assigned clinical score and the owner assigned 
visual analog score, when compared to placebo (P<0.05). Our results indicate that daily 
feeding with 30 g or 60 g of omega-3 PUFA feed supplement for 2 months in addition to 
management practices eliminating exposure to hay in the environment results in 
significant improvement in the clinical status of horses when compared to only providing 
low dust diet. 
	    	  






Chronic lower airway inflammatory diseases commonly occur in horses. Recurrent 
airway obstruction (RAO) is more prevalent in wet, cool climates in mature to older 
animals, while inflammatory airway disease (IAD) can occur under any environmental 
condition and can affect horses of any age, but tends to be more common in the younger 
population.1 
No definitive cure for RAO exists, however horses affected by both diseases can be 
managed long term by the combination of environmental management (minimizing dust 
exposure by housing and dietary changes) and medical therapy (anti–inflammatory 
medications and bronchodilators).2, 3 The recurrence rate for IAD is low, so horses 
suffering from this disease may achieve complete recovery with adequate long term 
management changes.4 The life-long management however, can require significant 
commitment (both time and financial) from owners. Ideal strict environmental control 
achieves maintenance of clinical remission in the majority of horses. Based on limited 
evidence in the human and veterinary literature, omega–3 PUFA containing feed 
supplements may be beneficial in improving clinical signs in horses affected by chronic 
lower airway inflammatory diseases.5-7
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The purpose of this study was to evaluate the clinical efficacy of an omega-3 PUFA 
containing equine feed supplement (Aleira™) in improving the clinical signs in horses 
affected by chronic lower airway disease. 
	    	  






Chronic lower airway inflammatory diseases of horses 
All equids can be affected by RAO, but females, horses older than 4 years of age and 
Thoroughbreds are more likely to be diagnosed based on a large scale retrospective 
study.8 The prevalence in North America and in Europe is estimated to be 14 % in the 
adult population.9, 10 A familial basis for the disease has been proposed, and an 
association between RAO in certain horse families and particular genes has been recently 
identified.11 Manifestation of the disease is triggered by environmental factors, including 
inhaled molds and organic dust (feed, hay, straw).12 Clinical disease is characterized by 
excessive mucus production in the airways, neutrophil accumulation, airway 
hyperresponsiveness and reversible bronchospasm. Common clinical signs include 
increased respiratory rate and effort at rest, coughing, nasal discharge and exercise 
intolerance. More severely affected cases can present in severe respiratory distress 
characterized by markedly increased respiratory rate and expiratory effort (“heave”), 
nostril flaring, anxious facial expression and reluctance to move.13 While history, clinical 
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signs and response to treatment are suggestive of the disease; definite diagnosis is 
achieved by cytological analysis of the lower respiratory tract secretions and lung 
function testing. Horses clinically affected with RAO will have a suppurative, non-septic 
inflammation 14 characterized by non-degenerative neutrophil percentage > 25% in the 
bronchoalveolar lavage fluid. Pulmonary function testing is a valuable tool to 
demonstrate reversibility of airway obstruction in horses affected with RAO and include 
measurements of dynamic lung compliance, pulmonary resistance, and maximal pleural 
pressure changes.15  
While RAO is a very well characterized clinical syndrome, IAD has been just recently 
defined as a separate clinical entity.1 Mostly younger to middle-aged horses are affected 
and as opposed to RAO cases, horses diagnosed with IAD have subtle to no clinical signs 
at rest, but exhibit decreased performance, coughing and excessive tracheal mucus 
accumulation. The pathogenesis of IAD is poorly defined however, noninfectious agents 
such as inhaled organic and inorganic particles are thought to play a central role in the 
development of the disease thereby causing mild to moderate allergic airway 
inflammation.16 Horses with IAD are diagnosed based on characteristic clinical signs, 
evidence of mucus accumulation in the trachea on airway endoscopy and cytology of 
bronchoalveolar lavage fluid that is characterized by mild neutrophilia (>5%), increased 
mast cell count (>2%) or eosinophil cell count (>1%).1 Pulmonary function testing does 
not provide consistently evidence for airway obstruction in horses diagnosed with IAD. 
Signs of airway hyperresponsiveness however, are present in horses with mastocytic or 
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eosinophilic inflammation, when they are exposed to nonspecific airway irritants, such as 
histamine aerosol.1, 16, 17  
The role of oxidative stress in recurrent airway obstruction 
 
Chronic airway inflammation, mediated by the overexpression of a large number of 
inflammatory genes, pro-inflammatory cytokines, chemokines and adhesion factors, is 
the key feature of recurrent airway obstruction.18 Reactive oxygen species released by 
inflammatory cells have also been shown to play a role in the pathogenesis of 
inflammatory airway diseases.19 The end products of this process, such as lipid 
hydroperoxides, phospholipids, aldehydes and isoprostanes promote lung inflammation.20 
Markers of oxidative stress including gluthatione, gluthatione disulphide and 8-
isoprostaneα have been shown to be increased in the BALF of RAO affected horses 
during an acute crisis.21 Studies have described the antioxidant status of RAO affected 
horses in clinical remission when compared to healthy controls,18 and the role of 
antioxidant supplementation on pulmonary performance and systemic anti-oxidant 
status.22 Based on this information, measurements of markers of oxidative stress along 
with levels of anti-oxidant substances (ascorbic acid and α−tocopherol) in the peripheral 
blood can provide adequate assessment of the magnitude of lipid peroxidation associated 
with the ongoing inflammation in the lungs. 
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Omega-3 polyunsaturated fatty acids in the management of respiratory 
inflammatory conditions in human medicine 
 
Increased consumption of omega-3 PUFAs, such as eicosopentaenoic acid (EPA) and 
docosahexanoic acid (DHA), results in greater integration of these fatty acids into the 
inflammatory cell phospholipids.23 The role of omega-3 PUFAs in inflammatory 
conditions is multifactorial. The incorporation of EPA and DHA occurs in a dose 
dependent fashion at the expense of arachidonic acid, and as a result, less substrate is 
available for the synthesis of eicosanoids during an inflammatory process. Another role 
of omega-3 PUFAs has been recently described, with the discovery of resolvins. These 
mediators are derived from EPA (E-series resolvins) and DHA (D-series resolvins), and 
have been shown to have direct anti-inflammatory properties.23 Additional roles of 
omega-3 PUFAs in inflammation include decreasing activation of nuclear factor kappa-
light-chain-enhancer of activated B cells and as a result, decreased generation of 
inflammatory cytokines like tumor necrosis factor-α, interleukin-1β (IL-1β), IL-6, IL-8, 
and expression of adhesion molecules. 
 
Multiple clinical studies have been undertaken to investigate the efficacy of omega-3 
PUFAs in chronic pulmonary inflammatory conditions in people with variable results.5, 23 
A trial in asthmatic children reported significant improvement in clinical scores, sputum 
evaluations and pulmonary function testing after supplementation with omega-3 PUFAs 
for 6 weeks at a dose of 1g/day.6 A study evaluating the response to a low-dose allergen 
challenge in asthmatic people revealed significantly decreased bronchial inflammation in 
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patients receiving 630 mg omega-3 PUFAs daily for 5 weeks compared to the placebo 
group7, while a higher dose of supplementation (780 mg/day) given only for 2 weeks 
didn’t improve pulmonary function in people with stable asthma.24 A study evaluating the 
effects of the daily intake of the lipid extract of the New Zealand green-lipped mussel 
that would provide 200 mg omega-3 PUFA daily in patients with atopic asthma, revealed 
a significant improvement in clinical signs (such as daytime wheezing) as well as in some 
lung function outcome measures (e.g. peak expiratory flow) when compared to placebo.25 
A clinical trial in patients suffering from seasonal asthma receiving 3g omega-3 PUFAs 
daily for 30 days revealed a significant improvement in pulmonary function testing that 
lasted only for a short period after treatment was discontinued, suggestive of a need for 
continuous administration.26 Based on these current studies, it appears that the doses as 
well as the length of supplementation play an important role in the overall efficacy of 
omega-3 PUFAs in the management of chronic lower airway conditions in people. 
 
 
Omega-3 polyunsaturated fatty acids in the management of inflammatory 
conditions in veterinary medicine 
 
There are only a limited number of trials published in the veterinary literature evaluating 
the effects of supplementation with omega-3 PUFAs in animals. Efficacy has been shown 
in the management of canine atopic dermatitis, where dogs were supplemented with 
different preparations of omega-3 PUFAs for 10 weeks, and then clinical scores were 
compared to the placebo group.27 In this experiment, while blood levels of the 
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supplemented omega-3 PUFAs increased significantly, the skin concentrations of omega-
3 PUFAs was not elevated and no correlation was found between clinical improvement 
and blood levels of the omega-3 PUFAs.  A study evaluating the production of 
inflammatory mediators during omega-3 PUFA supplementation in healthy dogs exposed 
to lipopolysaccharide challenge found that the placebo group had significantly higher 
serum activity of IL-1, IL-6, TNFα and prostaglandin E2 when compared to the treatment 
group.28 These results suggest the ability of omega-3 PUFA supplementation to decrease 
the effects of inflammation. An experimental trial assessing the effects of omega-3 PUFA 
administration for 4 weeks on airway hyperresponsiveness and inflammation in cats with 
experimentally-induced asthma revealed successful integration of polyunsaturated fatty 
acids in erythrocyte cell membranes and some beneficial effects on airway 
responsiveness through a leukotriene A2 dependent pathway.29 The most challenging 
aspect of omega-3 PUFA supplementation in horses is finding an effective dose that is 
yet reasonably priced. In a recent study, evaluating immune function of healthy yearling 
horses after omega-3 PUFA supplementation, the investigators found a dose of 6g/100 kg 
to effectively alter the composition of plasma and red blood cell phospholipids after a 35-
day supplementation period.30 This study however did not evaluate lower doses. A 
randomized, cross-over trial was reported on horses diagnosed with RAO and 
supplemented with sunflower oil (rich in linolenic acid) or seal blubber oil (rich in 
omega-3 PUFAs).31 A 10-week supplementation period revealed successful integration of 
omega-3 PUFAs into leukocyte membranes and a decrease in overall leukocyte count in 
the BAL fluid, but no effects on clinical score or pulmonary function were detected. 
While this study used a high dose of daily supplementation (65g/day),31 the lung function 
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measurements were taken after administration of sedation which would confound these 
measurement due to the bronchodilatory properties of the commonly used sedatives in 
horses (e.g. α2 agonists).32 Therefore, sedation prior to taking the measurements could 
potentially result is falsely improved values. Additionally, in this study, the authors did 
not include clinical parameters as outcome measures, which would have been helpful to 
judge the efficacy of treatment on chronic airway disease, as clinical signs often improve 
significantly prior to seeing improvement in pulmonary function or airway cytology. It is 
also important to mention, that, the horses in that study were fed hay for the duration of 
the experiments, therefore were constantly exposed to the dusty environment. 
Equine RAO and IAD present many similarities with asthma in people.33 Based on 
experiences in human asthma, feed supplements containing omega – 3 PUFAs have been 
proposed to improve clinical signs in horses with RAO.31  
The ultimate goal of our study was twofold: 
1. To find the minimal effective dose of a feed supplement containing omega-3 
PUFAs (Aleira™) that is able to alter the composition of phospholipid classes of 
plasma, in particular, increasing DHA fraction. 
2. To evaluate whether supplementation with Aleira™ is able to improve clinical 
scores, bronchoalveolar lavage (BAL) fluid cytological profile and 8-isoprostane 
levels and pulmonary function in horses with chronic lower airway disease fed a 
low-dust diet while being maintained in the same environment. 
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We hypothesized that daily administration of Aleira™ to horses with chronic lower 
airway disease along with low-dust diet for 8 weeks will result in greater improvement in 
clinical score, BAL fluid variables and pulmonary function when compared to horses fed 
placebo and low-dust diet. 
The rationale for the proposed research is that there is only limited scientific evidence 
that supports the beneficial effects of dietary supplementation with omega-3 PUFAs in 
horses affected by chronic lower airway inflammatory diseases. The data from our study 
would provide further information to support the usage of such supplements and 
specifically Aleira™. 
	    	  




MANUSCRIPT DRAFT FOR FUTURE SUBMISSION TO THE JOURNAL OF 
VETERINARY INTERNAL MEDICINE 
 
 
Chronic lower airway inflammatory diseases commonly occur in horses. Recurrent 
airway obstruction (RAO) is more prevalent in mature to older horses stabled in wet, cool 
climates, while inflammatory airway disease (IAD) can occur under any environmental 
condition and can affect horses of any age, but tends to be more common in the younger 
population.1 No definitive cure for RAO exists, however horses affected by both diseases 
can be managed long term by a combination of environmental management (minimizing 
dust exposure by implementing housing and dietary changes) and medical therapy (anti–
inflammatory medications and bronchodilators).2, 3 The recurrence rate for IAD is low, so 
horses suffering from this disease may achieve complete recovery with adequate long 
term management changes.4 The life-long management changes required for RAO 
affected horses however, can demand significant commitment (both time and financial) 
from owners. 
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Increased consumption of omega-3 PUFAs, such as eicosapentaenoic acid (EPA) and 
docosahexanoic acid (DHA), results in greater integration of these fatty acids into the 
inflammatory cell phospholipids.23 The role of omega-3 PUFAs in inflammatory 
conditions is multifactorial. The incorporation of EPA and DHA occurs in a dose 
dependent fashion at the expense of arachidonic acid, and as a result, less substrate is 
available for the synthesis of eicosanoids during an inflammatory process. Another role 
of omega-3 PUFAs has been recently described, with the discovery of resolvins. These 
mediators are derived from EPA (E-series resolvins) and DHA (D-series resolvins), and 
have been shown to have direct anti-inflammatory properties.23 Additional roles of 
omega-3 PUFAs in inflammation include decreasing activation of nuclear factor kappa-
light-chain-enhancer of activated B cells and as a result, decreased generation of 
inflammatory cytokines like tumor necrosis factor-α, interleukin-1β (IL-1β), IL-6, IL-8, 
and expression of adhesion molecules. 
Multiple clinical studies have been undertaken to investigate the efficacy of omega-3 
PUFAs in chronic pulmonary inflammatory conditions in people with variable results.5 A 
trial in asthmatic children reported significant improvement in clinical scores, sputum 
evaluations and pulmonary function testing after supplementation with omega-3 PUFAs 
for 6 weeks at a dose of 1g/ day.6 A study evaluating the response to a low-dose allergen 
challenge in asthmatic people revealed significantly decreased bronchial inflammation in 
patients receiving omega-3 PUFAs daily for 5 weeks compared to the placebo group7, 
while a higher dose of supplementation given only for 2 weeks didn’t improve pulmonary 
function in people with stable asthma.24 A clinical trial in patients suffering from seasonal 
asthma receiving 3g omega-3 PUFAs daily for 30 days revealed a significant 
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improvement in pulmonary function testing that lasted only for a short period after 
treatment was discontinued, suggestive of a need for continuous administration.26 
There are only a limited number of trials published in the veterinary literature evaluating 
the effects of supplementation with omega-3 PUFAs in animals. Efficacy has been shown 
in the management of canine atopic dermatitis27 and in cats with experimentally-induced 
asthma.29 The most challenging aspect of omega-3 PUFA supplementation in horses is 
finding the effective dose that is yet reasonably priced. In a recent study, evaluating 
immune function of healthy yearling horses after omega-3 PUFA supplementation, the 
investigators found a dose of 6g/100 kg to effectively alter the composition of plasma and 
red blood cell phospholipids after a 35-day supplementation period.30 A randomized, 
cross-over trial was reported in horses diagnosed with RAO and supplemented with 
sunflower oil (rich in omega-6 PUFAs) or seal blubber oil (rich in omega-3 PUFAs).31 A 
10-week supplementation period revealed successful integration of omega-3 PUFAs into 
leukocyte membranes and a decrease in overall leukocyte count in the BAL fluid, but no 
effects on clinical score or pulmonary function. While this study used a high dose of daily 
supplementation (65g/day), administration of sedation confounded the pulmonary 
function testing results questionable.31 
The purpose of the study was to evaluate the clinical efficacy of an omega-3 PUFA-rich 
equine feed supplement in horses affected by chronic lower airway disease. We 
hypothesized that daily administration of the omega-3 PUFA supplement to horses with 
chronic lower airway disease along with low-dust diet for 8 weeks will result in greater 
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improvement in clinical score, BAL fluid variables and pulmonary function when 
compared to horses fed placebo and low-dust diet. 
 
MATERIALS AND METHODS 
 
Experimental design, animals 
 Pilot study: four healthy horses and four previously diagnosed RAO affected horses 
were selected from the Purdue University Herd to participate in the dose determination 
study. They were divided into 2 groups: Group 1, encompassing 2 healthy and 2 RAO 
affected horses, was started on the omega-3 PUFA supplementation at the lowest dose 
recommended by the manufacturer (1X= 30 g/day); Group 2, encompassing 2 healthy 
and 2 RAO affected horses, was started on the omega-3 PUFA supplementation at a 
double dose (2X= 60 g/day). Horses underwent a thorough physical examination before 
enrollment into the study and venous blood samples were collected to determine serum 
phospholipid profiles. 
 
Horses were monitored daily during the trial for general attitude and appetite. Physical 
examination including clinical scoring was performed weekly. Blood was collected every 
2 weeks to determine plasma phospholipid profiles. After the first 2 weeks, the dosages 
were doubled (the group receiving the supplement at a 1x dose was continued at a 2x 
dose, while the groups receiving the supplement at a 2x dose was continued at a 4x dose). 
Horses then were maintained on the same dose and blood samples continued to be 
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collected every 2 weeks to determine plasma phospholipid profiles, until < 10% change 
in omega-3 PUFA ratio was identified compared to previous measurements, suggestive of 
a plateau effect. Once plateau was reached, supplement administration was discontinued. 
Efficacy study: Sample size calculation based on previously published clinical 
data from client applied visual analog scoring (VAS)33 showed that n ≥ 32 horses would 
be needed to allow detection of 30% improvement in VAS (breathing score and cough) 
post-treatment with an 80 % power and a significance level α = 0.05. The study was 
performed over a 9-month period as a randomized, placebo-controlled, double-blinded 
clinical trial. Client-owned horses were recruited by advertisements and mails sent out to 
referring veterinarians and brought to the Purdue University Veterinary Teaching 
Hospital (PUVTH) for testing. Horses were enrolled if they had history of chronic 
respiratory disease of at least 3-month duration and exhibited clinical signs of lower 
airway inflammation at the time of recruitment with at least one of the following: 
increased breathing rate or effort at rest, intermittent cough, or poor performance. After 
obtaining client consent, horses underwent a thorough physical examination including 
clinical scoring, blood collection, pulmonary function testing and BAL fluid collection on 
the day of enrollment (day 0). Only horses with a normal leukogram and no clinical 
evidence of infectious respiratory disease were included in the study. Horses then 
returned home after they were randomly assigned to receive one of three treatments 
(omega-3 PUFA supplement 1x or 2x, or placebo) as a daily feed supplement for 8 weeks, 
while their attitude and appetite were monitored daily by the owners. They were 
maintained in the same environment as before enrollment into the study but their diet was 
	    	  
	   	   	  
	  
16 
switched to complete pelleted feeda and no exposure to hay was authorized during the 
study period. Coupons for free bags of feed were given to owners to cover needs during 
the trial and compliance to these rules was assessed during history taking at recheck visit. 
All medications were withheld during the study period. Owners were asked to assign a 
visual analog score (VAS, see Appendix A and B) for performance, breathing difficulty 
and cough upon enrollment and then once a week (day 7, 14, 21, 28, 35, 42, 49 and 56).34 
At the end of the supplementation period (day 56), horses returned to PUVTH to undergo 
the same procedures as on Day 0.  
Horses were diagnosed with IAD based on BAL fluid cytology showing either >1% 
eosinophil count, >2% mastocyte count or >10% neutrophil count along with 
characteristic clinical signs (cough, exercise intolerance), and a maximum change in 
transpulmonary pressure (∆PLmax) less than 15 cmH2O, while horses with chronic 
respiratory disease and ∆PLmax > 15 cmH2O  were diagnosed with RAO. 
The Purdue University Animal Care and Use Committee approved the study. 
 
Feed supplement administration and housing 
Pilot study: horses were maintained in outside dirt paddocks and were brought in 
a stall to receive the feed supplement as a top dressing on complete pelleted feeda fed at 2% 
of bodyweight daily. 
Efficacy study: horses were randomly selected by an online randomization 
generatorb to receive the omega-3 PUFA feed supplement (1x or 2x dose) or placebo as a 
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top dressing on pelleted feed once daily for 8 weeks. During the study period horses were 
fed a diet of complete pelleted feeda based on individual energy requirements (1.5 – 2% 
of bodyweight) with no access to hay. 
 
Clinical evaluation 
Physical examination was performed weekly during the pilot study, while it was 
performed twice on client owned horses (day 0 & 56). Physical examination included 
evaluation of hydration and perfusion parameters, cardiac and thoracic auscultation, 
rectal temperature, and body weight. 
Two previously adopted clinical scoring systems were used to assess respiratory 
compromise in the efficacy study at the time of initial assessment and at the end of the 
supplementation period based on 1) respiratory rate, respiratory effort, nasal discharge, 
and presence or absence of cough and abnormal lung sounds (range 0-21); 2) abdominal 
effort and nostril flaring (range 2-8). (Appendix C)35, 36 Additionally, owners were 
instructed on how to quantify performance, breathing difficulty and cough using a visual 
analog scale (VAS, score 0-100) and were asked to record it weekly from day 0 to 56 
(Appendix A, B).34 Qualification for enrollment in the study included a VAS score of 70 
or less in at least one of the 3 categories with a score of 100 indicating absence of clinical 
signs. 
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Venipuncture was performed on the left or the right external jugular vein with a 20G 
x1.5-inch needle connected to an evacuated tube containing EDTA. Complete blood 
count analysis was performed on a commercially available automated hematology 
analyzer. Plasma samples were centrifuged 10 minutes at 3400g and stored at -80 °C until 
further processing. 
Fatty acid analysis of plasma was carried out on freshly thawed sample after extraction of 
lipids by the Folch method37, isolation of phospholipids by thin layer chromatography, 
methylation utilizing boron trifluoride and gas chromatography as described previously.38 
 
Pulmonary function testing (PFT) 
Horses were restrained in stocks without sedation. An esophageal balloon catheter (inside 
diameter, 4.8 mm; outside diameter, 6.4 mm; length, 240 cm) was advanced through the 
nose to mid-thorax as described before.15 The exact position of the catheter was recorded 
for each horse at baseline testing and used in the subsequent measurements. A second 
catheter of same size and diameter was used to measure pressure within the mask and 
both catheters were connected to a differential pressure transducer.c Maximum change in 
transpulmonary pressure (∆PLmax) was defined as the difference between pleural and 
mask pressures during peak inspiratory and expiratory effort. A mask was placed over the 
nose of each horse with a pneumotachometerd coupled to a differential pressure 
transducere that measured a signal proportional to airflow. Signals produced by the 
pneumotachometer and the pressure transducers were recorded by computer software. 
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Resistance (RL) was measured using the isovolume 50% method. Dynamic compliance 
(Cdyn) was computed by dividing tidal volume by the difference in ∆PLmax between points 
of zero flow. 
After completion of standard lung function mechanics, horses were sedated with a 
combination of detomidine (0.02 mg/kg) and butorphanol (0.02 mg/kg) in preparation for 
the BAL.  
 
Bronchoalveolar lavage (BAL) fluid sampling and analysis 
Bronchoalveolar lavage was performed with a BAL tube after lung function 
measurements were obtained.15 Tubing and containers in contact with BAL fluid were 
sterile. The caudo-dorsal area of the left or right diaphragmatic lobes was sampled at 
random. Five hundred milliliters of sterile 0.9% NaCl was infused and retrieved from the 
airways in 3 aliquots. The BAL fluid was immediately placed on ice and processed 
within 20 minutes of collection. Cytological specimens were prepared by centrifugation 
and processed with Wright’s stain. For 8-isoprostane concentrations, aliquots of 2ml 
BAL treated with 0.005% butylated hydroxytoluene were stored at -80C until analysis via 
an enzyme immune assay, using an enzyme immunoassay kitf validated in the horse.18 
The BAL tube was cleaned and sterilized after each procedure. 
 
 
	    	  




Data distribution was assessed using the Shapiro-Wilk test for normality. The data in the 
pilot study were not normally distributed. The effect of dose (1x vs. 2x) and disease 
status (healthy vs. RAO) was tested by analysis of covariance (ANCOVA) using post-
treatment variable as outcome variable and pre-treatment variable as covariate.39 If 
significant effect was detected then, post-hoc analysis was conducted using Friedman 
analysis of variance (ANOVA) when comparing repeated measurements between week 0 
and 8 or Mann-Whitney U test when comparing between groups at a given time point. 
 
Data from the efficacy study were not normally distributed. The effect of dose (placebo 
vs. 1x vs. 2x) and disease status (IAD vs. RAO) were tested using ANCOVA.  Data were 
compared between baseline and 2 months following treatment with Wilcoxon matched 
pairs tests. Data were compared between treatment groups at each time point using 
Kruskal-Wallis ANOVA (3 treatment groups: Placebo, 1x, 2x) or Mann-Whitney U test 
(2 treatment groups: Placebo, treatment [1x or 2x]). Owner-assigned scores (VAS) 
between week 0 and 8 were compared using Friedman ANOVA. Post-hoc paired 
comparisons of VAS scores between week 0 and subsequent weeks were performed using 
Wilcoxon matched pairs tests with Bonferroni adjusted p-value (0.05/7=0.0071; 
P<0.0071). 
All data were expressed as median [25% - 75% quartiles]. P<0.05 was considered 
significant except for comparison of weekly VAS scores were P<0.0071 was considered 
significant. 
	    	  





All horses (n=8) enrolled in the pilot study remained healthy throughout the experiments. 
There were 5 geldings and 3 mares in the study, aged between 11-26 years. Regarding the 
breed distribution, there were 3 Quarter Horses, 2 Paints and one of each: Appaloosa, 
Thoroughbred, Tennessee Walking Horse. All RAO affected horses involved in this trial 
remained in clinical remission, there were no differences between physical exam findings 
and plasma lipid proportions between the healthy and RAO affected horses, therefore the 
data from both groups were pooled. The only significant difference between the groups 
receiving the different doses (1x vs. 2x) was for oleic acid (18:1n9c) where relative 
plasma levels decreased in horses receiving 2x dose during 4 weeks (P=0.018) but did not 
change in those fed 1x dose.  
Subsequently, data from horses receiving 1x or 2x Aleira were pooled.  Horses receiving 
the 2x dose of Aleira were only supplemented for 4 weeks, as their PUFA profile did not 
differ from the 1x group. The relative amount of DHA (expressed as % of total fatty acids) 
increased significantly between week 0 and 4 of supplementation and then reached a 
plateau between week 4 and 8  (P=0.012). 
 
Efficacy study 
There were a total of 35 horses evaluated for the dose efficacy study. Out of these horses, 
34 qualified, as there was one horse that was diagnosed with upper respiratory tract 
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obstruction on the initial evaluation, and 32 horses completed the trial. One of the horses 
that dropped out died of colic approximately 1 month after enrollment in the study. No 
necropsy was performed due to lack of consent from the owner, but he horse was 
reported to be well up until the onset of colic, and according to the VAS scoring sheet, 
showed clinical improvement in his respiratory signs. Therefore we believe that the colic 
was unrelated to the supplement administration. Another horse was excluded from the 
final data analysis due to lack of compliance from the owners, as they disclosed that they 
started feeding hay again during the trial. 
Regarding the sex distribution, there were 18 geldings, 11 mares and 3 stallions. The age 
of the horses ranged between 6-22 years. Regarding breed distribution, there were 13 
Quarter Horses, 6 Walking Horses, 3 Arabians, 2 Appaloosas and one of each: 
Thoroughbred, Mustang, Saddlebred, Warmblood and Paint. Three horses were of 
unknown breed. 
Eleven horses received placebo feed supplement, ten were fed the supplement at the 
recommended label dose (1x) and eleven horses received twice the labeled dose (2x). All 
the horses included in the data analysis were maintained on a complete pelleted feed for 
the entire duration of the study, with no exposure to hay. None of the owners reported 
any adverse effects related to the supplementation, all horses accepted the supplement or 
placebo well, and consumed it readily mixed with the pelleted feed. 
Fourteen horses were diagnosed with RAO and 18 with IAD based on clinical evaluation, 
lung function testing and cytological analysis of the bronchoalveolar fluid. On baseline 
evaluation, there was a statistically significant difference between IAD and RAO cases in 
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regards to pulmonary function test results, such as ΔPmax (8.9 ± 3.0 and 26.6 ± 15.8 
cmH2O in IAD and RAO horses, respectively; P<0.0001), Cdyn (1.9 ± 0.8 and 1.2 ± 0.7 
L/cmH2O in IAD and RAO horses, respectively; P=0.02) and RL (0.7 ± 0.3 and 1.9 ± 1.2 
cmH2O/L/s in IAD and RAO cmH2O horses, respectively; P<0.001). Additionally, the 2 
groups differed in regards to the neutrophil granulocyte percentage in the BAL fluid 
(P=0.01). Other clinical parameters, such as the veterinarian assigned clinical scores, 
owner assigned VAS and physical exam findings; the fatty acid profiles and 8-
isoprostane levels in the BAL fluid were not different between the 2 groups at baseline 
evaluation. No difference in treatment effect was detected between horses with RAO or 
IAD horses therefore; data analysis was subsequently performed on data pooled among 
all horses with chronic respiratory disease. 
 
At baseline, none of the variables were different between placebo and treatment groups. 
Data analysis with the 3 different groups (placebo, 1x, 2x) revealed only one significant 
treatment effect (VAS cough). Post-hoc analysis revealed that VAS cough improved 
significantly (i.e. increased) in all 3 treatment groups (placebo, 1x, 2x) however, horses 
treated with 1x dose of omega-3 PUFA supplement exhibited a significantly higher VAS 
cough score 2 months later than horses receiving placebo (P=0.043). (Figure 1.) As there 
was no additional effect associated with the different doses of supplementation noted, 
data from horses treated with 1x and 2x dose of omega-3 PUFA supplement were pooled 
and compared to data from horses treated with placebo. 
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Clinical signs - The effect of treatment with the supplement on clinical signs was 
statistically significant as compared to placebo. Post-hoc analyses showed that clinician 
assigned clinical scores (both long and short scores) in horses treated with the omega-3 
PUFA supplement (1x or 2x) exhibited a significant improvement (P<0.001) however; 
scores at the end of supplementation were not different between the placebo and 
treatment groups (Figure 2). When evaluating the owner-assigned clinical scores (VAS 
cough, respiratory effort, performance), they all improved significantly in the placebo and 
treatment horses over time, however VAS cough and VAS respiratory effort scores 2 
months after treatment showed a significantly greater improvement in horses given the 
omega-3 PUFA supplement compared to placebo (P=0.031) (Figure 3).  Clinical data is 
summarized in Table 1. 
According to the VAS scoring sheets filled out by the owners on a weekly basis, the 
effect of supplementation and low dust diet on clinical signs were noticeable during the 
first 2 weeks of therapy and reached maximum benefit between weeks 2-5 for coughing, 
weeks 5-6 for respiratory effort and weeks 3-5 for poor performance (Figure 4). 
BAL fluid analysis – Omega-3 PUFA supplementation for 2 months resulted in a 
significant decrease in the relative proportion of inflammatory cells (neutrophils) in the 
lung mucus, and this effect was not observed in horses fed the placebo (Figure 5; Table 
1). Isoprostane concentrations in BAL fluid were not significantly affected by treatment. 
(Table 1.) 
Lung function testing - Two months of supplementation improved lung function 
(decreased ΔPLmax and RL) in both placebo and omega-3 PUFA treated horses however, 
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the effect only reached statistical significance in horses fed the omega-3 PUFA 
supplement (P<0.01) (Figure 6). 
Phospholipid analysis of plasma - The only fatty acid that was significantly affected by 
omega-3 PUFA treatment was DHA whereby 2 month of supplementation resulted in a 




This study is the first report evaluating the effects of an omega-3 PUFA containing feed 
supplement administered to horses affected with chronic lower airway inflammatory 
disease and concurrently fed a low dust diet. The pilot study confirmed that the dose 
recommended by the manufacturer (30 g/day) is able to alter the phospholipid classes of 
plasma, and results in a rise of DHA levels. Results from the double-blind, placebo-
controlled trial showed that administration of the omega-3 PUFA supplement provided 
additional clinical benefits when compared to the control group maintained in a low dust 
environment and fed placebo. 
In this study we elected to use both horses diagnosed with RAO and IAD. We were 
interested to see, if there would be a difference in response to omega-3 PUFA 
administration with the different chronic lower airway inflammatory diseases. At baseline 
evaluation, the difference in disease status was clearly seen in pulmonary function test 
results and cytological analysis of the BAL fluid, while overall clinical assessment was 
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not different between the RAO and IAD groups. This is not unexpected, as horses with 
IAD do not have evidence of airway obstruction based on standard lung mechanics15 and 
often have mastocytic and eosinophilic inflammation present in the BAL fluid1, 
compared to RAO horses, that have increased  ΔPLmax and RL and severe neutrophilic 
inflammation in BAL fluid.10 As we were mostly interested in clinical response to the 
supplementation and there were no differences in treatment effect based on disease 
category, we elected to pool data from RAO and IAD horses and perform data analysis 
regardless of disease status. 
A previous study evaluated omega-3 PUFA supplementation in horses with RAO,31 but 
failed to detect a significant treatment effect in pulmonary function. The study used a 
high dose of supplementation (65 g/day) especially when compared to our study, where a 
lower dose of the omega-3 PUFA supplement did result in significant treatment effect. In 
that experiment, however horses received sedation (detomidine and butorphanol) before 
performance of lung function testing that may have contributed to the negative overall 
results, as the sedatives used can result in bronchodilation.32, 40 Additionally, horses were 
fed hay throughout the study period, so they were continuously exposed to the dusty 
environment which would likely diminish any potential benefit provided by PUFA 
supplementation. In the present study, improvement was noted in horses receiving 
omega-3 PUFA supplementation regarding clinical parameters, including the veterinarian 
assigned clinical score that evaluated the degree of respiratory compromise, the owner 
assigned VAS that evaluated the coughing and the respiratory effort of the horse, and the 
number of inflammatory cells in the BAL fluid as well as in the lung function. Limiting 
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dust exposure in the environment by removing hay from the diet results in clinical 
improvement in horses with lower airway inflammatory diseases,35 so some degree of 
improvement was expected in all treatment groups just by switching the horses’ diet from 
hay to pelleted feed. We thought this design would allow a more accurate evaluation of 
the effect of omega-3 PUFA supplementation, as horses in severe crisis would have been 
unlikely to show clinical improvement just with the feed supplement administration. This 
experimental design would also standardize the influence of dietary difference between 
horses and represent the typical management change that practitioners would recommend 
in the field. 
Owner assessment of clinical signs in horses with chronic airway disease has been 
previously reported by Gerber et al to be successful in judging efficacy of a certain 
treatment.34 We used data from that study for sample size calculation in order to detect a 
30% improvement in VAS scores that was deemed clinically relevant. When comparing 
the efficacy of the omega-3 PUFA supplement and environmental modification to the 
dexamethasone treated group in Gerber’s study, interestingly the magnitude of 
improvement in the VAS cough and respiratory effort scores is comparable between the 
two studies. This result is surprising, and suggests that the low dust diet along with the 
omega-3 PUFA supplement administered to horses with chronic airway disease for 8 
weeks have similar benefits as a shorter course (3 weeks) of dexamethasone 
administration (0.1 mg/kg, q24h). This effect is most likely due to the combination of 
allowing the respiratory tract to clear the allergens by limiting exposure as seen in the 
placebo group and allowing adequate integration of omega-3 PUFAs into the 
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inflammatory cell membranes and altering the inflammation over an extended period of 
time. 
Inflammation in an acute RAO crisis has been associated with increased levels of 
markers of oxidative stress in the airways.21 Interestingly, measurements of 8-isoprostane 
from the BAL fluid did not reveal any changes when compared to baseline levels in our 
study. One possible explanation is that oxidative stress in the airways was not directly 
affected by the treatment, or it is possible that 8-isoprostane levels did not accurately 
reflect the redox state of the horses in the study, and measurements of other markers of 
oxidative stress such as reduced or oxidized glutathione would have been more accurate 
for such evaluation. It is also possible, that the low dose supplement was able to modify 
some aspects of the inflammatory response responsible for clinical improvement, without 
affecting oxidative stress. In a follow up project, it would be interesting to evaluate 
cytokine levels in the BAL fluid before and after supplementation, to see if a cause and 
effect relationship can be identified.  
Measurement of fatty acid classes in plasma was also performed, and revealed a 
statistically significant increase in plasma DHA levels in the treatment group when 
compared to baseline values, which was not observed in the placebo group. These results 
of the fatty acid analysis allow us to believe that the increase in DHA levels in blood 
could have been responsible for the clinical improvement in the horses receiving the 
supplement, when compared to the placebo group. The DHA dose used in this study was 
based on the recommendations of the manufacturer of the product. According to label, 
the daily recommended dose of 30 grams of the supplement that is recommended daily, 
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contains 1.5 grams of DHA per serving. Additionally to the dose recommended by the 
manufacturer, we evaluated administration of a double dose to determine whether a 
higher dose would result in additional improvement of clinical signs. It was concluded 
that a single dose of the supplement (1 scoop = 30 grams) appeared to be as beneficial as 
the double dose (2 scoops = 60grams). No additional benefits in clinical signs, lung 
function or cytological analysis of the BAL fluid were noted with the increased dose. 
This finding is interesting, as it has been shown previously that, incorporation of omega-3 
PUFAs into the inflammatory cell membrane occur in a dose dependent fashion41, 
therefore a greater improvement would be expected with the higher dose. The dose of 1.5 
grams DHA/day was able to alter the phospholipid classes of plasma, and resulted in a 
significant rise in DHA % in plasma in both pilot and clinical trial, despite that the DHA 
dose used in this study was much lower than reported previously in horses.30 42 43 The 
experiments in the literature however did not include lower doses to evaluate integration 
of omega-3 PUFA in blood. According to our findings, feeding the 2x dose did not 
proportionally increase plasma levels of DHA. It is possible, that there is a limit of how 
much omega-3 PUFA can be absorbed and integrated in the horse and higher doses of 
supplementation do not carry additional health benefits. Another possible explanation is 
that the source of the omega-3 PUFA makes a difference. The supplement used in our 
study was from an algae source, which has not been evaluated in horses before.  
It is important to note that there were other ingredients in the supplement, such as 
Vitamin C, methylsulfonylmethane and mushroom complex which may have contributed 
to decreasing inflammation. MSM has been shown to improve clinical signs of 
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inflammation in people with hay fever,44 while Vitamin C has been proposed to decrease 
exercise induced bronchoconstriction in people.45 However, vitamin C was also included 
in the placebo product. According to the manufacturer, the proprietary mushroom 
complex is supposed to provide additional antioxidant properties to the supplement. Since 
oxidative stress measurement using 8-isoprostane didn’t reveal any difference between 
placebo and treatment group, it is unlikely that clinical benefits observed in the treatment 
group were due to the mushroom complex rather than the DHA supplementation. 
Measurements of additional oxidative stress and inflammatory markers in blood may 
have allowed us to draw more definitive conclusions on the effect on these other 
compounds as compared to omega-3 PUFA supplementation. 
When evaluating a feed supplement to incorporate in the daily practice for life-long 
management, palatability and ease of administration are key factors. Horses in this study 
readily accepted the supplement, and owners reported it to be easy to administer, making 
it feasible for long term, convenient administration. Results from this study are 
comparable to other studies, where inhaled steroids and low dust diet were used to 
achieve and maintain clinical remission in horses.2 When the ease of administration is 
taken into consideration, horse owners are more likely to be compliant with adding a 
supplement to the feed, than administrating medications to the horse on a daily basis (oral 
or inhaled), not to mention the potential side effects associated with long term steroid 
administration.46 
It has been shown previously, that horses suffering from chronic lower airway 
inflammatory disease (both RAO and IAD) greatly benefit from reducing dust in the 
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environment,1, 12 however some horses even on strict environmental control require 
rescue medications when experiencing a flare up. Based on the present study, a natural 
omega-3 PUFA containing feed supplement, could be an additional option to help 
manage these horses long term, and maintain them in a more stable remission, when 
compared to the low dust environment by itself.  Future studies should determine the 
optimal duration of supplementation that result in resolution of pulmonary inflammation 
and whether the supplement may prevent exacerbation of respiratory disease in horses 
exposed to dusty environment. In order to find a direct relationship between the omega-3 
PUFA administration and the clinical improvement, a future study may focus on 
measurements of markers of inflammation, and cytokines in the BAL fluid. Additionally, 
it would be important to evaluate, whether administration of a lower dose would be 
similarly effective, decreasing the cost associated with the continuous administration. 
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FIGURES AND TABLES 
Table 1: Summarized data from the efficacy study. * Statistically significant difference 
between placebo and treatment. † Statistically significant difference between before and 
after supplementation. 
 















Long score  8.5±4.6 5.6±5.2 8.8±4.0 3.4±2.1† 
Short score 4.7±1.6 3.8±1.5 4.6±1.7 2.9±1.1† 
VAS cough 39.2±22.3 68.8±30.6† 46.7±29.0 89.4±19.5†* 
VAS respiratory 
effort 
43.3±21.9 68.4±25.5† 52.8±32.0 85.8±23.2†* 
VAS 
performance 
40.0±29.2 65.4±30.7† 56.0±36.8 80.0±30.9† 
ΔPmax (cmH2O) 11.6±5.8 9.0±6.2 19.5±15.9 10.1±6.2† 
Rl (cmH2O/L/s) 0.85±0.48 0.63±0.52 1.5±1.2 0.75±0.48† 
Cdyn (L/cmH2O) 2.1±0.91 2.5±1.5 1.3±0.7 2.9±2.8 
BAL 
Neutrophil% 
19.6±16.2 22.4±21.3 31.4±25.1 15.4±19.8† 
DHA % in 
plasma 
0.1±0.09 0.21±0.27 0.01±0.11 0.45±0.22† 
8-isoprostane 17.8±12.1 17.2±11.8 16.3±9.2 18.4±11.9 
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Figure 1: VAS cough before and 2 month after daily treatment with placebo or 1x or 2x 
dose of the omega-3 supplement. *	  Significantly different from baseline (week 0; P<0.05).  
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Figure 2: Clinician-assigned long score (range: 0-21) in horses with chronic respiratory 
disease treated for 2 months with daily placebo or the omega-3 supplement. *	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Figure 3: Effect of feed supplementation on VAS cough score of horses with chronic 
respiratory disease treated for 2 months. * Significantly different from week 0 (P<0.05).  








	    	  






Figure 4: Weekly change in VAS cough (A) and respiratory effort (B) scores in horses 
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Figure 5: Effect of feed supplementation on the proportion of inflammatory cells 
(neutrophils) in the bronchoalveolar lavage (BAL) fluid of horses with chronic 
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Figure 6: Effect of feed supplementation on maximum transpulmonary pressure change 
(ΔPLmax) in horses with chronic respiratory disease treated for 2 months. * Significantly 
different from week 0 (P=0.0065). 
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Figure 7: DHA level expressed as % of total fatty acids in plasma sample of horses with 
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a Equine Senior, Purina Mills 
b www.random.org 
c DP/45-30, Validyne Engineering Corp, Northridge, CA 
d No. 4 Fleisch, EMKA Technologies, Paris, France 
e DP/45-14, Validyne Engineering Corp, Northridge, CA 
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• The omega-3 PUFA feed supplement is safe to be used in horses, all horses 
accepted the supplement, and consumed it readily mixed with the pelleted feed. 
No adverse effects were seen in any of the research horses or reported by the 
clients. 
• Our pilot study confirmed that the dose recommended by the manufacturer (30 
grams of the supplement daily, containing 1.5 grams of DHA) is able to alter the 
phospholipid classes of plasma, and results in a rise of DHA levels. Results from 
the double-blind, placebo-controlled trial showed that administration of the 
omega-3 PUFA supplement provided additional benefits when compared to the 
control group maintained in a low dust environment and fed placebo.  
• In our study, statistically significant improvement was noted in multiple clinical 
parameters, including the veterinarian assigned clinical score that evaluated the 
degree of respiratory compromise; the owner assigned VAS that evaluated the 
coughing and the respiratory effort of the horse, the number of inflammatory cells 
in the BAL fluid as well as the lung function. 
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• The magnitude of improvement in the VAS cough and respiratory effort scores is 
comparable to the effect of dexamethasone therapy in RAO horses in previous 
studies. This suggests that the low dust diet along with the omega-3 PUFA 
supplement administered to horses with chronic airway disease for 8 weeks have 
similar benefits as a shorter course (3 weeks) of dexamethasone administration.  
• Measurements of 8-isoprostane from the BAL fluid (which has been identified as 
a marker of oxidative stress, present in high concentration in the BAL fluid of 
horses with RAO) did not reveal any changes when compared to baseline levels in 
our study.  
• Measurement of fatty acid classes in plasma revealed a statistically significant 
increase in plasma DHA levels in the treatment group when compared to baseline 
values, which was not observed in the placebo group. These results of the fatty 
acid analysis suggest that the increase in DHA levels in blood could have been 
responsible for the clinical improvement in the horses receiving the supplement, 
when compared to the placebo group.  
• No additional benefits in clinical signs, lung function or cytological analysis of 
the BAL fluid were noted with doubling the dose of daily supplementation.  
• Based on the present study, a natural omega-3 PUFA containing feed supplement, 
could be an additional alternative to manage horses with RAO and IAD long term, 
and maintain them in a more stable remission, when compared to the low dust 
environment by itself.   
• Future studies should determine the optimal duration of Aleira supplementation 
that result in resolution of pulmonary inflammation and whether the supplement 
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may prevent exacerbation of respiratory disease in horses exposed to dusty 
environment.  
• It would be also important to evaluate, whether administration of a lower dose 
would be similarly effective, decreasing the cost associated with the continuous 
administration. 
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Appendix A: Page 1 of the VAS scoring sheet sent home with the owners. 
 
Please score your horse’s health status based on these 3 parameters 1x/week during the 
study. Use the guidelines detailed on the other side of this paper to assign a score. 
Please bring this form with you to the recheck appointment. 
Assign a score between 0 – 100. 
In all categories, a higher score is associated with a better health status. 
	   Date	   Coughing	   Respiratory	  effort	   Exercise	  
intolerance	  
Week	  0	  	   	   	   	   	  
Week	  1	   	   	   	   	  
Week	  2	   	   	   	   	  
Week	  3	   	   	   	   	  
Week	  4	   	   	   	   	  
Week	  5	   	   	   	   	  
Week	  6	   	   	   	   	  
Week	  7	   	   	   	   	  
Week	  8	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Permanent, severe: Score 0 	  
Occasional, after work or feeding: Score 50 




Poor, in severe distress all the time: Score 0 
Minimally acceptable: Score 50 




Poor: Score 0 
Minimally acceptable: Score 50 
Excellent: Score 100 
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Appendix C1: Form for the clinician assigned clinical score – Long score 
 
 
Clinical scoring system (adapted from Tesarowski, 1996) 
Respiratory rate (breaths/min)  < 15      0 
16-20      1  
21-25 2 
26-29 3 
>30      4 
Nasal discharge    None      0 
      Serous      1 
      Mucopurulent     3 
Abdominal lift   None       0 
     Mild (perceptible heave line)    1 
     Pronounced (abdomen, thorax, and anal movement) 3 
Nasal flaring    None      0 
      Present      1 
Tracheal sounds   Normal (tubular sound)    0 
      Increase in intensity    1 
      Mucus movement    3 
Crackles    None      0 
      Present      2 
Wheezes    None      0 
      Present      2 
Cough     None      0 
      Intermittent     1 
      Paroxysmal     3 
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Appendix C2: Form for the clinician assigned clinical score - Short score. 
 
 
Clinical scoring system (adapted from Rush, 1998) 
Circle the score that applies to the horse 
 
a) Nostril flaring 
 
Normal, no signs        1 
Slight, occasional flaring of nostrils      2 
Moderate nostril flaring       3 
Severe continuous flaring during each respiration    4 
 
b) Abdominal effort of exhalation 
 
Normal, no signs        1 
Slight abdominal component       2 
Moderate abdominal component      3 
Severe, marked abdominal component     4 
 
 
 Total score (a + b)   
	  
